Sodium Thiosulfate to Reduce Hearing Impairment for Adults Receiving Cisplatin for Solid Tumor Cancer

Inclusion Criteria

• Participants have provided informed consent prior to initiation of any study-specific activities
• At least 18 years of age, male and female, at the time of signing the informed consent
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Histologically or cytologically confirmed treatment-naïve cancer
• Scheduled to receive a Food and Drug Administration (FDA)-approved, on-label indication, standard of care systemic cisplatin-based regimen (at least 200 mg/m^2 cumulative dose) for any untreated any solid malignancy deemed by the treating physician

Exclusion Criteria

• Prior cisplatin exposure due to a cancer treatment history
• Concurrent ototoxic medication unable to be safely discontinued or switched to a non-toxic alternative
• Planned radiation to the head or neck prior to, during, or within 3 months of completion of cisplatin
• History of severe hypersensitivity to sulfite, sodium thiosulfate, or any components
• Baseline serum sodium > 145 mmol/L or any grade ≥ 3 electrolyte abnormality
• Cisplatin infusion duration greater than 6 hours
• Females during pregnancy or breastfeeding, and childbearing potential, unwilling to use a method of contraception during treatment
• Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment
• Subject likely not to be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (i.e., Clinical Outcome Assessments) to the best of the subject’s and investigator's knowledge
• History or evidence of any other clinically significant disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the investigator, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion